top of page

Search


Concerns Grow Over Potential Delays in FDA Drug Approvals Amid Government Cuts
FDA drug approval delays due to government cuts are happening but not widespread yet. Early signs and staffing challenges suggest the situation could worsen over time.
5 days ago


Survey Predictions on New Drugs May Miss Mark on Budget Impact
Jeffrey Casberg, M.S., Vice President of Clinical Pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy Survey results.
6 days ago


Systemic Gaps Hinder Cell and Gene Therapy Adoption and Access
espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.
May 12


Cardinal Health: 2025 Advanced Therapies Report
In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.
May 9


Specialty Drugs Dominate Pharmaceutical Frontier in 2025
In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Apr 15


Nonopioid Pain Drug Journavx Gaining Traction With High Potential
Journavx is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use
Mar 25


Can Global Policies Boost Biosimilar Adoption Work in the US?
On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...
Nov 17, 2024


Biosimilar Interchangeability: FDA Designation, Marketing Exclusivity, Guidance, and Future Trends
Biologics are regulated by the FDA and are approved under the 351(a) pathway with a Biologics License Application (BLA).
Nov 11, 2024


How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
Nov 18, 2021


Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
Nov 1, 2021


An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
Oct 27, 2021


Further Dissecting the Launch of Adalimumab Biosimilars in the US
According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.
Apr 21, 2021


EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner
Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.
Oct 8, 2020


Will COVID-19 Clog Generics, Biologics Pipeline?
IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.
May 15, 2020


IPD Analytics Experts Discuss Humira's Influence on Biosimilars
IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network
Apr 29, 2020


IPD Analytics Experts Discuss the Insulin Pipeline
With conversion of the BLA pathway, new launches may receive interchangeability. New insulin products are being launched in the near future
Apr 27, 2020


Drug Pipeline for 2020 Strong in Generics, Biosimilars
According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.
Apr 22, 2020


A Look at the Generic and Biosimilar Drug Pipeline
IPD Analytics discussed both the generic and biosimilar drugs coming to market, and implications for managed care pharmacy at AMCP eLearning
Apr 21, 2020


AMCP Presenters Predict 4 More Biosimilar Launches in 2020
The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.
Apr 21, 2020


Express Scripts Coverage, FDA Label Update Boost Rybelsus
There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.
Jan 23, 2020
bottom of page